When a patient presents with a first demyelinating event and MRI reveals two or more brain lesions with imaging characteristics consistent with multiple sclerosis, a specific evidence-based management pathway applies.
Single clinical demyelinating event with 2 or more brain lesions on MRI whose characteristics are consistent with multiple sclerosis — a presentation that places patients at elevated risk for further episodes and warrants early clinical decision-making.
Management centres on an individualized discussion of risks and benefits, after which disease-modifying therapy (DMT) may be initiated for patients who opt for treatment. The specific agents, selection criteria, and sequencing details are covered in the full protocol.
DOI: 10.1212/WNL.0000000000005347
Clinicians should discuss the benefits and risks of DMTs for people with a single clinical demyelinating event with 2 or more brain lesions that have imaging characteristics consistent with MS (Level B).
After discussing the risks and benefits, clinicians should prescribe DMT to people with a single clinical demyelinating event and 2 or more brain lesions characteristic of MS who decide they want this therapy (Level B).
View source ↗